Indication for the treatment & control of Benign Prostatic Hyperplasia (BPH).
5-Alpha Reductase Inhibitor; Urogenital/Anhispasmodics
Finasteride, a competitive inhibitor of the 5α reductase enzyme which is used in the treatment of benign prostatic hyperplasia. It is selective for 5α reductase type 2 enzyme and has no affinity for androgen receptors. The development of the prostate gland and subsequent BPH is dependent upon conversion of testosterone to dihydrotestosterone (DHT) within the prostate. Finasteride belongs to a new class of specific inhibitors of 5α reductase, an intracellular enzyme, which metabolises testosterone into the more potent androgen, DHT. Finasteride has no affinity for the androgen receptor.
Finasteride (5 mg) daily with or without food.
No clinically important drug interactions have been identified. Finasteride does not appear to significantly affect the cytochrome P450 linked drug metabolising enzyme system. Compounds which have been tested in man include Propranolol, Digoxin, Glibenclamide, Warfarin, Theophylline, and antipyrine.
Hypersensitivity to any component of this product; women who are or may become pregnant; children, people with severely diminished urinary flow.
Finasteride is well tolerated. The most frequently reported side-effects have been related to sexual function. In clinical studies the following effects have been reported in ? 1% of patient treated for 12 months with 5mg a day of Finasteride : impotence (3.7%), decreased libido (3.3%) decreased volume of ejaculate (2.8%).
Finasteride is contra-indicated in women who are or may become pregnant. It is not known whether Finasteride is excreted in human milk.
Store at cool and dry place (below 30°C). Protect from light and moisture. Keep all the medicines out of the reach of children.
.png&w=384&q=75)